Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: Role of Src homology 2-containing inositol 5′-phosphatase interaction with c-Abl

Diabetologia

Volumn 56, Issue 6, 2013, Pages 1327-1338

  Mokhtari, D ^a   Al Amin, A ^a   Turpaev, K ^b,c   Li, T ^a   Idevall Hagren, O ^a   Li, J ^a   Wuttke, A ^a   Fred, R G ^a   Ravassard, P ^d   Scharfmann, R ^e   Tengholm, A ^a   Welsh, N ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b VAVILOV INSTITUTE OF GENERAL GENETICS   (Russian Federation)

^c CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

^d INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^e INSTITUT COCHIN   (France)

Author keywords

c Abl; Cell death; EndoC H1 cells; Imatinib mesilate; Insulin producing cells; PIP3 signalling; SHIP2

Indexed keywords

ABELSON KINASE; BETA CATENIN; HYDROGEN PEROXIDE; IMATINIB; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; SERINE; SUNITINIB; WORTMANNIN;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NITROSATIVE STRESS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BENZAMIDES; CELL MEMBRANE; CELL SURVIVAL; CELLS, CULTURED; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; INDOLES; INSULIN; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PIPERAZINES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PTEN PHOSPHOHYDROLASE; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84877772971     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2868-2     Document Type: Article

References (50)

1. Maekawa T, Ashihara E, Kimura S (2007) The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome positive leukemias. Review. Int J Clin Oncol 12:327-340
2. David T, Nicholas W, Tyler J et al (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20:5054-5058
3. Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G (2004) Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Onocol 22:4653-4655
4. Veneri D, Franchini M, Bonora E (2005) Imatinib and regression of type 2 diabetes. N Engl J Med 352:1049-1050
5. Tsapas A, Vlachaki E, Sarigianni M, Klonizakis F, Paletas K (2008) Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML). Leuk Res 32:674-675
6. Breccia M, Muscaritoli M, Alimena G. (2005) Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib. Haematologica 90(Suppl.):ECR21
7. Agostino N, Chinchilli VM, Lynch CJ et al (2010) Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 17:197-202
8. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC (2010) Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 95:3763-3767
9. Mariani S, Tornaghi L, Sassone M et al (2010) Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. Leuk Res 34:e5-e7
10. Hägerkvist R, Jansson L, Welsh N (2008) Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond) 114:65-71
11. Han MS, Chung KW, Cheon HG et al (2009) Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes 58:329-336
12. Gur S, Kadowitz PJ, Hellstrom WJ (2010) A protein tyrosine kinase inhibitor, imatinib mesylate (gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats. J Sex Med 7:3341-3350
13. Hägerkvist R, Sandler S, Welsh N (2007) Gleevec-mediated protection against diabetes of the NOD mouse and the streptozotocin-injected mouse: possible role of beta-cell NF-kB activation and anti-apoptotic preconditioning. FASEB J 21:618-628
14. Hägerkvist R, Makeeva N, Elliman S, Welsh N (2006) Imatinib mesylate (Gleevec) protects against STZ-induced diabetes and islet cell in vitro. Cell Biol Int 30:1013-1017
15. Louvet C, Szot GL, Lang J et al (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 105:18895-18899
16. Reber L, Da Silva CA, Frossard N (2006) Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 533:327-340
17. Vogel WF, Abdulhussein R, Ford CE (2006) Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal 18:1108-1116
18. Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24
19. Templeton A, Brändle M, Cerny T, Gillessen S (2008) Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 19:824-825
20. Rhodes CJ, White MF (2002) Molecular insights into insulin action and secretion. Eur J Clin Invest 32(suppl 3):3-13
21. Suwa A, Kurama T, Shimokawa T (2010) SHIP2 and its involvement in various diseases. Expert Opin Ther Targets 14:727-737
22. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM (1998) Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280:1614-1617
23. Clément S, Krause U, Desmedt F et al (2001) The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409:92-97
24. Wang L, Liu Y, Yan Lu S et al (2010) Deletion of Pten in pancreatic β-cells protects against deficient ß-cell mass and function in mouse models of type 2 diabetes. Diabetes 59:3117-3126
25. Elghazi L, Rachdi L, Weiss AJ, Cras-Méneur C, Bernal-Mizrachi E (2007) Regulation of b-cell mass and function by the Akt/protein kinase B signaling pathway. Diab Obes Metab 9:147-157
26. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO (2006) Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2281:9971-9976
27. Liu Z, Habener JF (2008) Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 283:8723-8735
28. Liu Z, Habener JF (2009) Stromal cell-derived factor-1 promotes survival of pancreatic β-cells by the stabilisation of β-catenin and activation of transcription factor 7-like 2 (TCF7L2). Diabetologia 52:1589-1598
29. Dabernat S, Secrest P, Peuchant E (2009) Lack of β-catenin in early life induces abnormal glucose homoeostasis in mice. Diabetologia 52:1608-1617
30. Genua M, Pandini G, Cassarino MF, Messina RL, Frasca F (2009) c-Abl and insulin receptor signalling. Vitam Horm 80:77-105
31. Ravassard P, Hazhouz Y, Pechberty S, Bricout-Neveu E, Armanet M, Czernichow P, Scharfmann R (2011) A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion. J Clin Invest 121:3589-3597
32. Dyachok O, Idevall-Hagren O, Sågetorp J et al (2008) Glucose-induced cyclic AMP oscillations regulate pulsatile insulin secretion. Cell Metab 8:26-37
33. Tian G, Sågetorp J, Xu Y et al (2012) Role of phosphodiesterases in the shaping of sub-plasma membrane cAMP oscillations and pulsatile insulin secretion. J Cell Sci 125:5084-5095
34. Prasad NK, Werner ME, Decker SJ (2009) Specific tyrosine phosphorylations mediate signal-dependent stimulation of SHIP2 inositol phosphatase activity, while the SH2 domain confers and inhibitor effect to maintain the basal activity. Biochemistry 14:6285-6287
35. Wong YH, Lee TY, Liang HK et al (2007) KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns. Nucl Acids Res 35:W588-W594
36. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20:5010-5018
37. Brown A, Browes C, Mitchell M, Montano X (2000) C-abl is involved in the association of p53 and trk A. Oncogene 19:3032-3040
38. Koch A, Scherr M, Breyer B et al (2008) Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover. Oncogene 27:4678-4689
39. Cipres A, Abassi YA, Vuori K (2007) Abl functions as a negative regulator of Met-induced cell motility via phosphorylation of the adapter protein CrkII. Cell Signal 19:1667-1670
40. Frasca F, Vigneri P, Vella V, Vigneri R, Wang JYJ (2001) Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor. Oncogene 20:3845-3856
41. Lin C-I, Whang EE, Moalem J, Ruan DT (2012) Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma. Surgery 152:1045-1050
42. Idevall Hagren O, Tengholm A (2006) Glucose and insulin synergistically activate phosphatidylinositol 3-kinase to trigger oscillations of phosphatidylinositol 3,4,5-trisphosphate in beta-cells. J Biol Chem 281:39121-39127
43. Wisniewski D, Strife A, Swendeman S et al (1999) A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 15:2707-2720
44. Grempler R, Leicht S, Kischel I, Eickelmann P, Redemann N (2007) Inhibition of SH2-domain containing inositol phosphatase 2 (SHIP2) in insulin producing INS1E cells improves insulin signal transduction and induces proliferation. FEBS Lett 581:5885-5890
45. Sasaoka T, Fukui K, Wada T et al (2005) Inhibition of endogenous SHIP2 ameliorates insulin resistance caused by chronic insulin treatment in 3T3-L1 adipocytes. Diabetologia 48:336-344
46. Odriozola L, Singh G, Hoang T, Chan AM (2007) Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. J Biol Chem 282:23306-23315
47. Klinger S, Poussion C, Debril MB et al (2008) Increasing GLP-1-induced β-cell proliferation by silencing negative regulation of signaling cAMP response element modulator-α and DUSP14. Diabetes 57:584-593
48. Mokhtari D, Welsh N (2009) Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 118:241-247
49. Little PJ, Cohen N, Morahan G (2009) Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes. Sci World J 9:224-228
50. Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293-1300